Application of PPARalpha agonist in treatment of psoriasis
The invention provides an application of a PPAR alpha agonist or a pharmaceutically acceptable salt thereof in preparation of a drug for treating psoriasis, and the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is used as an active ingredient and dissolved in a carrier solution...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SHI YULING ZHUANG YU MA RUI MEI HAO SHE XIAOMIN CAI JIANGLUYI GUO CHUNYUAN CUI LIAN CHEN QIANYU YANG NAN YAO LINGLING WANG YUANYUAN |
| description | The invention provides an application of a PPAR alpha agonist or a pharmaceutically acceptable salt thereof in preparation of a drug for treating psoriasis, and the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is used as an active ingredient and dissolved in a carrier solution to prepare the drug for treating psoriasis, wherein the PPARalpha agonist is WY14643, the carrier solution is a mixed solution of polyethylene glycol and ethanol, and the molecular weight of the polyethylene glycol is 200-600; in the medicine, the final concentration of the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is 2-20mM, and the volume ratio of polyethylene glycol to ethanol is 9: 1-1: 9. The invention verifies the curative effect and the specific action mechanism of WY14643 on psoriasis for the first time: inhibiting the mRNA expression level of important chemotactic factors of psoriasis in keratinocytes; the WY14643 can effectively treat psoriasis, activate PPARalpha in skin, relieve |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN118615292A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN118615292A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN118615292A3</originalsourceid><addsrcrecordid>eNrjZLByLCjIyUxOLMnMz1PIT1MICHAMSswpyEhUSEzPz8ssLlHIzFMoKUpNLMlNzSsBqSgozi_KTCzOLOZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGFmaGpkaWRo7GxKgBAFaFLts</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application of PPARalpha agonist in treatment of psoriasis</title><source>esp@cenet</source><creator>SHI YULING ; ZHUANG YU ; MA RUI ; MEI HAO ; SHE XIAOMIN ; CAI JIANGLUYI ; GUO CHUNYUAN ; CUI LIAN ; CHEN QIANYU ; YANG NAN ; YAO LINGLING ; WANG YUANYUAN</creator><creatorcontrib>SHI YULING ; ZHUANG YU ; MA RUI ; MEI HAO ; SHE XIAOMIN ; CAI JIANGLUYI ; GUO CHUNYUAN ; CUI LIAN ; CHEN QIANYU ; YANG NAN ; YAO LINGLING ; WANG YUANYUAN</creatorcontrib><description>The invention provides an application of a PPAR alpha agonist or a pharmaceutically acceptable salt thereof in preparation of a drug for treating psoriasis, and the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is used as an active ingredient and dissolved in a carrier solution to prepare the drug for treating psoriasis, wherein the PPARalpha agonist is WY14643, the carrier solution is a mixed solution of polyethylene glycol and ethanol, and the molecular weight of the polyethylene glycol is 200-600; in the medicine, the final concentration of the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is 2-20mM, and the volume ratio of polyethylene glycol to ethanol is 9: 1-1: 9. The invention verifies the curative effect and the specific action mechanism of WY14643 on psoriasis for the first time: inhibiting the mRNA expression level of important chemotactic factors of psoriasis in keratinocytes; the WY14643 can effectively treat psoriasis, activate PPARalpha in skin, relieve</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240910&DB=EPODOC&CC=CN&NR=118615292A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76419</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240910&DB=EPODOC&CC=CN&NR=118615292A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHI YULING</creatorcontrib><creatorcontrib>ZHUANG YU</creatorcontrib><creatorcontrib>MA RUI</creatorcontrib><creatorcontrib>MEI HAO</creatorcontrib><creatorcontrib>SHE XIAOMIN</creatorcontrib><creatorcontrib>CAI JIANGLUYI</creatorcontrib><creatorcontrib>GUO CHUNYUAN</creatorcontrib><creatorcontrib>CUI LIAN</creatorcontrib><creatorcontrib>CHEN QIANYU</creatorcontrib><creatorcontrib>YANG NAN</creatorcontrib><creatorcontrib>YAO LINGLING</creatorcontrib><creatorcontrib>WANG YUANYUAN</creatorcontrib><title>Application of PPARalpha agonist in treatment of psoriasis</title><description>The invention provides an application of a PPAR alpha agonist or a pharmaceutically acceptable salt thereof in preparation of a drug for treating psoriasis, and the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is used as an active ingredient and dissolved in a carrier solution to prepare the drug for treating psoriasis, wherein the PPARalpha agonist is WY14643, the carrier solution is a mixed solution of polyethylene glycol and ethanol, and the molecular weight of the polyethylene glycol is 200-600; in the medicine, the final concentration of the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is 2-20mM, and the volume ratio of polyethylene glycol to ethanol is 9: 1-1: 9. The invention verifies the curative effect and the specific action mechanism of WY14643 on psoriasis for the first time: inhibiting the mRNA expression level of important chemotactic factors of psoriasis in keratinocytes; the WY14643 can effectively treat psoriasis, activate PPARalpha in skin, relieve</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLByLCjIyUxOLMnMz1PIT1MICHAMSswpyEhUSEzPz8ssLlHIzFMoKUpNLMlNzSsBqSgozi_KTCzOLOZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGFmaGpkaWRo7GxKgBAFaFLts</recordid><startdate>20240910</startdate><enddate>20240910</enddate><creator>SHI YULING</creator><creator>ZHUANG YU</creator><creator>MA RUI</creator><creator>MEI HAO</creator><creator>SHE XIAOMIN</creator><creator>CAI JIANGLUYI</creator><creator>GUO CHUNYUAN</creator><creator>CUI LIAN</creator><creator>CHEN QIANYU</creator><creator>YANG NAN</creator><creator>YAO LINGLING</creator><creator>WANG YUANYUAN</creator><scope>EVB</scope></search><sort><creationdate>20240910</creationdate><title>Application of PPARalpha agonist in treatment of psoriasis</title><author>SHI YULING ; ZHUANG YU ; MA RUI ; MEI HAO ; SHE XIAOMIN ; CAI JIANGLUYI ; GUO CHUNYUAN ; CUI LIAN ; CHEN QIANYU ; YANG NAN ; YAO LINGLING ; WANG YUANYUAN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN118615292A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SHI YULING</creatorcontrib><creatorcontrib>ZHUANG YU</creatorcontrib><creatorcontrib>MA RUI</creatorcontrib><creatorcontrib>MEI HAO</creatorcontrib><creatorcontrib>SHE XIAOMIN</creatorcontrib><creatorcontrib>CAI JIANGLUYI</creatorcontrib><creatorcontrib>GUO CHUNYUAN</creatorcontrib><creatorcontrib>CUI LIAN</creatorcontrib><creatorcontrib>CHEN QIANYU</creatorcontrib><creatorcontrib>YANG NAN</creatorcontrib><creatorcontrib>YAO LINGLING</creatorcontrib><creatorcontrib>WANG YUANYUAN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHI YULING</au><au>ZHUANG YU</au><au>MA RUI</au><au>MEI HAO</au><au>SHE XIAOMIN</au><au>CAI JIANGLUYI</au><au>GUO CHUNYUAN</au><au>CUI LIAN</au><au>CHEN QIANYU</au><au>YANG NAN</au><au>YAO LINGLING</au><au>WANG YUANYUAN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application of PPARalpha agonist in treatment of psoriasis</title><date>2024-09-10</date><risdate>2024</risdate><abstract>The invention provides an application of a PPAR alpha agonist or a pharmaceutically acceptable salt thereof in preparation of a drug for treating psoriasis, and the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is used as an active ingredient and dissolved in a carrier solution to prepare the drug for treating psoriasis, wherein the PPARalpha agonist is WY14643, the carrier solution is a mixed solution of polyethylene glycol and ethanol, and the molecular weight of the polyethylene glycol is 200-600; in the medicine, the final concentration of the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is 2-20mM, and the volume ratio of polyethylene glycol to ethanol is 9: 1-1: 9. The invention verifies the curative effect and the specific action mechanism of WY14643 on psoriasis for the first time: inhibiting the mRNA expression level of important chemotactic factors of psoriasis in keratinocytes; the WY14643 can effectively treat psoriasis, activate PPARalpha in skin, relieve</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN118615292A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Application of PPARalpha agonist in treatment of psoriasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A06%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHI%20YULING&rft.date=2024-09-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN118615292A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |